Keyphrases
Venous Thromboembolism
80%
Multiple Myeloma
67%
Anticoagulation
32%
Thromboprophylaxis
30%
Thrombosis
24%
Direct Oral Anticoagulants
23%
Confidence Interval
21%
American Society of Hematology
21%
United States Veterans
21%
Apixaban
20%
Hemostasis
19%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Patients with COVID-19
18%
In Cancer
18%
Bleeding
18%
Living Guidelines
17%
Enzalutamide
17%
Abiraterone
17%
Cancer-associated Venous Thromboembolism
16%
Malignancy
16%
Patients with Cancer
14%
Retrospective Cohort Study
13%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
13%
Chemotherapy
12%
COVID-19
12%
Monoclonal Gammopathy of Undetermined Significance
12%
Warfarin
11%
Dose Reduction
11%
Venous Thromboembolism Risk
11%
Body Mass Index
10%
High Risk
10%
Overall Survival
10%
Coronavirus Disease (COVID)
10%
Anticoagulants
10%
Hematological Malignancies
9%
Hospitalization
9%
Secondary Prevention
9%
Cancer Patients
9%
Grading of Recommendations
9%
Evaluation Assessment
9%
Assessment Development
9%
Comorbid Diseases
9%
Major Bleeding
9%
Comparative Effectiveness
9%
Venous Thromboembolism Treatment
9%
Frailty
9%
US Veterans
8%
Cancer-associated Thrombosis
8%
Statins
8%
Reduced Dose
8%
Medicine and Dentistry
Venous Thromboembolism
100%
Multiple Myeloma
50%
Thrombosis
38%
COVID-19
34%
Anticoagulation
33%
Thromboprophylaxis
30%
Malignant Neoplasm
26%
Bleeding
22%
Hematology
21%
Blood Stasis
19%
Direct Oral Anticoagulant
18%
Clinician
18%
Apixaban
17%
Cancer
15%
Hematologic Malignancy
14%
Diffuse Large B-Cell Lymphoma
13%
Odds Ratio
10%
Cancer Treatment
10%
Drug Dose Reduction
9%
Major Bleeding
9%
Hazard Ratio
9%
Retrospective Cohort Study
9%
Secondary Prevention
9%
Antithrombotic
9%
Thrombocytopenia
8%
CHOP
8%
Pancreas Cancer
8%
Sarcopenia
8%
Monoclonal Gammopathy of Undetermined Significance
8%
Myeloma
8%
Critical Illness
7%
Diseases
7%
Anticoagulant Therapy
6%
Randomized Controlled Trial
6%
Acute Disease
6%
Overall Survival
6%
Body Mass Index
6%
Risk Stratification
5%
Lenalidomide
5%
Low Molecular Weight Heparin
5%
Rivaroxaban
5%
International Classification of Diseases
5%
Health Outcomes
5%
Dexamethasone
5%
Phlebothrombosis
5%
Randomized Clinical Trial
5%
Pancreas Adenocarcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
52%
Multiple Myeloma
50%
Thrombosis
23%
Malignant Neoplasm
19%
Chemotherapy
18%
Bleeding
17%
Enzalutamide
17%
Abiraterone
17%
Diffuse Large B Cell Lymphoma
14%
Cohort Study
14%
Direct Oral Anticoagulant
13%
Diseases
13%
Warfarin
13%
Prostate Cancer
13%
Monoclonal Immunoglobulinemia
12%
Apixaban
10%
Hematologic Malignancy
9%
Frailty
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Myeloma
8%
Overall Survival
7%
Lenalidomide
5%
Dexamethasone
5%